BBI 5000Alternative Names: BBI-5000
Latest Information Update: 07 Dec 2015
At a glance
- Originator Unknown
- Developer Brickell Biotech
- Class Skin disorder therapies
- Mechanism of Action Prostaglandin D2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atopic dermatitis